Literature DB >> 8888383

Effects of nicotine and amphetamine on latent inhibition in human subjects.

J C Thornton1, S Dawe, C Lee, C Capstick, P J Corr, P Cotter, S Frangou, N S Gray, M A Russell, J A Gray.   

Abstract

Latent inhibition (LI) is a phenomenon in which repeated non-reinforced exposure to a stimulus retards subsequent conditioning to that stimulus; it reflects a process whereby irrelevant stimuli become ignored, and has been the subject of study concerning attentional abnormalities in schizophrenia. Low doses of the indirect dopamine (DA) agonists, amphetamine and nicotine, disrupt LI in the rat. These drugs are believed to disrupt LI via DA release in the nucleus accumbens; LI in amphetamine- and nicotine-treated rats is reinstated by administration of the DA antagonist haloperidol. In human subjects, low doses of amphetamine abolish LI, and more recently haloperidol has been shown to potentiate LI. The present study investigated the effects of nicotine on LI in human subjects, and also attempted to replicate the abolition of LI by amphetamine. Nicotine failed to affect LI when administered either subcutaneously or by cigarette smoking. LI was, however, abolished in a group of subjects given 5 mg amphetamine 90 min before testing. Supplementary analyses of the data pooled from all three experiments showed that, in contrast to an earlier report, LI was no weaker in smokers than in nonsmokers.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8888383     DOI: 10.1007/bf02805990

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  50 in total

1.  Drowsiness due to chlorpromazine in relation to cigarette smoking. A report from the Boston Collaborative Drug Surveillance Program.

Authors:  C Swett
Journal:  Arch Gen Psychiatry       Date:  1974-08

2.  Differential performance of acute and chronic schizophrenics in a latent inhibition task.

Authors:  I Baruch; D R Hemsley; J A Gray
Journal:  J Nerv Ment Dis       Date:  1988-10       Impact factor: 2.254

3.  Evidence that tobacco smoking increases the density of (-)-[3H]nicotine binding sites in human brain.

Authors:  M E Benwell; D J Balfour; J M Anderson
Journal:  J Neurochem       Date:  1988-04       Impact factor: 5.372

4.  Latent inhibition of conditioned dopamine release in rat nucleus accumbens.

Authors:  A M Young; M H Joseph; J A Gray
Journal:  Neuroscience       Date:  1993-05       Impact factor: 3.590

5.  Latent inhibition and blocking: further consideration of their construct validity as animal models of schizophrenia Commentary on Ellenbroek and Cools "Animal models with construct validity for schizophrenia"

Authors:  M.H. Joseph; S.H. Jones
Journal:  Behav Pharmacol       Date:  1991-12       Impact factor: 2.293

6.  Latent inhibition is not affected by acute or chronic administration of 6 mg/kg dl-amphetamine.

Authors:  I Weiner; A Izraeli-Telerant; J Feldon
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

7.  Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance.

Authors:  M W Jann; S R Saklad; L Ereshefsky; A L Richards; C A Harrington; C M Davis
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

8.  Normalization of auditory physiology by cigarette smoking in schizophrenic patients.

Authors:  L E Adler; L D Hoffer; A Wiser; R Freedman
Journal:  Am J Psychiatry       Date:  1993-12       Impact factor: 18.112

9.  Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET.

Authors:  N S Gray; L S Pilowsky; J A Gray; R W Kerwin
Journal:  Schizophr Res       Date:  1995-09       Impact factor: 4.939

Review 10.  Neural substrates of latent inhibition: the switching model.

Authors:  I Weiner
Journal:  Psychol Bull       Date:  1990-11       Impact factor: 17.737

View more
  14 in total

1.  Sex-dependent antipsychotic capacity of 17β-estradiol in the latent inhibition model: a typical antipsychotic drug in both sexes, atypical antipsychotic drug in males.

Authors:  Michal Arad; Ina Weiner
Journal:  Neuropsychopharmacology       Date:  2010-07-07       Impact factor: 7.853

Review 2.  Cholinergic modulation by opioid receptor ligands: potential application to Alzheimer's disease.

Authors:  William C Motel; Andrew Coop; Christopher W Cunningham
Journal:  Mini Rev Med Chem       Date:  2013-03       Impact factor: 3.862

3.  The visual search analogue of latent inhibition: implications for theories of irrelevant stimulus processing in normal and schizophrenic groups.

Authors:  R E Lubow; Oren Kaplan
Journal:  Psychon Bull Rev       Date:  2005-04

4.  Disruption of the US pre-exposure effect and latent inhibition in two-way active avoidance by systemic amphetamine in C57BL/6 mice.

Authors:  Tilly Chang; Urs Meyer; Joram Feldon; Benjamin K Yee
Journal:  Psychopharmacology (Berl)       Date:  2006-12-19       Impact factor: 4.530

5.  Contrasting effects of increased and decreased dopamine transmission on latent inhibition in ovariectomized rats and their modulation by 17beta-estradiol: an animal model of menopausal psychosis?

Authors:  Michal Arad; Ina Weiner
Journal:  Neuropsychopharmacology       Date:  2010-03-17       Impact factor: 7.853

6.  Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia.

Authors:  Tatiana Lipina; Viviane Labrie; Ina Weiner; John Roder
Journal:  Psychopharmacology (Berl)       Date:  2005-03-10       Impact factor: 4.530

7.  Learned irrelevance and associative learning is attenuated in individuals at risk for psychosis but not in asymptomatic first-degree relatives of schizophrenia patients: translational state markers of psychosis?

Authors:  Ariane T Orosz; Joram Feldon; Andor E Simon; Leonie M Hilti; Kerstin Gruber; Benjamin K Yee; Katja Cattapan-Ludewig
Journal:  Schizophr Bull       Date:  2010-01-15       Impact factor: 9.306

8.  A pre-clinical study showing how dopaminergic drugs administered during pre-exposure can impair or facilitate latent inhibition.

Authors:  N A Schmajuk; J A Gray; J A Larrauri
Journal:  Psychopharmacology (Berl)       Date:  2004-08-13       Impact factor: 4.530

9.  Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat.

Authors:  Mark D Black; Geoffrey B Varty; Michal Arad; Segev Barak; Amaya De Levie; Denis Boulay; Philippe Pichat; Guy Griebel; Ina Weiner
Journal:  Psychopharmacology (Berl)       Date:  2008-08-16       Impact factor: 4.530

10.  Haloperidol and clozapine antagonise amphetamine-induced disruption of latent inhibition of conditioned taste aversion.

Authors:  Holger Russig; Aneta Kovacevic; Carol A Murphy; Joram Feldon
Journal:  Psychopharmacology (Berl)       Date:  2003-07-25       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.